IP Library › Patent Application 18550883

Patent Application

App. No. 18/550,883

MACROCYCLES AS CFTR MODULATORS

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US None
App. No.: 18/550,883

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention relates to macrocyclic compounds of Formula (I) wherein Ar 1 , Ar 2 , R 1 , R 2 , R 3 , R 4 , and X are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as modulators of CFTR.

Claims (239)

1 . A compound of Formula (I)

wherein

X represents —CR X1 R X2 , wherein

R X1 and R X2 together with the carbon atom to which they are attached form a ring which is:

C 3-6 -cycloalkan-1,1-diyl;

C 5-6 -cycloalkan-1,1-diyl which is fused to a benzene ring;

C 3-6 -cycloalkan-1,1-diyl, wherein said C 3-6 -cycloalkan-1,1-diyl group independently is mono-substituted with C 1-3 -alkoxy, fluoro, or hydroxy; or di-substituted with fluoro;

C 4-6 -heterocycloalkan-diyl, wherein said C 4-6 -heterocycloalkan-diyl contains one ring nitrogen atom, wherein said nitrogen when having a free valency is unsubstituted or mono-substituted wherein the substitutents are independently selected from C 1-4 -alkyl, and —COO—C 1-3 -alkyl; or

C 4-6 -heterocycloalkan-diyl, wherein said C 4-6 -heterocycloalkan-diyl contains one ring oxygen atom;

R X1 and R X2 both independently represent C 1-4 -alkyl; or

R X1 represents hydrogen, and

R X2 represents

hydrogen;

C 1-6 -alkyl;

C 1-4 -fluoroalkyl;

C 3-6 -cycloalkyl;

C 1-3 -alkyl wherein said C 1-3 -alkyl is mono-substituted with

hydroxy;

C 1-4 -alkoxy;

-L X1 -C 3-6 cycloalkyl wherein said C 3-6 -cycloalkyl is unsubstituted or di-substituted with fluoro; and wherein L X1 independently represents a direct bond or oxygen;

C 4-6 -heterocycloalkyl wherein said C 4-6 -heterocycloalkyl contains one ring oxygen atom;

-NR N1 R N2 wherein R N1 and R N2 together with the nitrogen form a 4- to 6-membered carbocyclic ring comprising the nitrogen atom, wherein said ring is mono- or di-substituted with fluoro;

a partially aromatic bicyclic ring, which is

-L X2 -Ar X2 wherein—

L X2 independently represents a direct bond, C 1-3 -alkylene, —C 1-3 -alkylene-O—*, or —C 1-3 -alkylene-O—C 1-2 -alkylene-*; wherein the asterisks indicate the bond that is attached to the group Ar X2 ; and

ArX 2 independently represents aryl, or 5- to 10-membered heteroaryl; wherein said group Ar X2 independently is unsubstituted, or mono-, or di-substituted wherein the substituents are independently selected from

C 1-4 -alkyl;

C 1-3 -alkoxy;

halogen;

C 3-6 -cycloalkyl;

C 1-3 -fluoroalkyl; and

Ar X3 wherein Ar X3 independently represents phenyl, or 5- or 6-membered heteroaryl; wherein said group Ar X3 independently is unsubstituted, or mono-, or di-substituted wherein the substituents independently are selected from C 1-3 -alkyl, C 1-3 -alkoxy, C 1-3 -alkoxy-C 2-3 -alkyl, C 3-5 -cycloalkyl, C 1-3 -fluoroalkyl, and halogen;

and

R 1 independently represents

hydrogen;

—C 1-6 -alkyl;

—C 2-6 -alkyl wherein said C 2-6 -alkyl is mono-substituted with hydroxy, or C 1-4 -alkoxy;

—C 1-6 -alkyl wherein said C 1-6 -alkyl is mono-substituted with R 11 ; wherein R 11 independently represents

a saturated 5- or 6-membered heterocycloalkyl containing one or two ring heteroatoms wherein said heteroatoms are independently selected from nitrogen and oxygen, wherein said 5- or 6-membered heterocycloalkyl is independently unsubstituted, mono- or di-substituted, wherein the substituents independently are selected from C 1-4 -alkyl, halogen, and benzyl;

C 3-6 -cycloalkyl, wherein said C 3-6 -cycloalkyl is unsubstituted or mono-substituted with C 1-4 -alkoxy;

phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or 5- or 6-membered heteroaryl independently is unsubstituted, mono- or di-substituted wherein the substitutents independently are selected from C 1-4 -alkyl, C 1-4 -alkoxy, C 1-3 -fluoroalkyl, C 1-3 -fluoroalkoxy, halogen, cyano, and morpholin-4-yl;

benzyloxy;

a spirocyclic fragment, which is

a saturated bicyclic ring, which is

a partially aromatic bicyclic ring, which is

or the fragment

represents a heterocyclic ring which is

wherein R X represents

hydrogen;

C 1-4 -alkyl;

C 3-6 -cycloalkyl;

C 1-4 -alkyl, wherein said C 1-4 -alkyl is mono-substituted with C 3-4 -cycloalkyl;

C 2-4 -alkyl, wherein said C 2-4 -alkyl is mono-substituted with hydroxy or C 1-3 -alkoxy;

phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or 5- or 6-membered heteroaryl independently is unsubstituted, mono- or di-substituted wherein the substituents independently are selected from C 1-4 -alkyl, C 1-3 -alkoxy, C 1-3 -fluoroalkyl, C 1-3 -fluoroalkoxy, cyano or halogen;

wherein R SX1 represents hydrogen or —CO—O—C 1-4 -alkyl;

—CO—R OX1 , or —SO 2 —R OX1 ; wherein R OX1 independently represents

C 1-4 -alkyl;

C 1-3 -alkyl wherein said C 1-3 -alkyl is mono-substituted with C 1-3 -alkoxy, tetrahydropyranyl, morpholin-4-yl, phenyl, 10-membered heteroaryl, or —NR ONX1 R ONX2 wherein R ONX1 and R ONX2 independently represent hydrogen or C 1-3 -alkyl;

tetrahydropyranyl;

a group of the structure (R X-A ):

wherein (A) represents a non-aromatic 5- or 6-membered ring fused to the phenyl group, wherein ring (A) comprises two heteroatoms independently selected from oxygen and nitrogen; wherein said ring (A) independently is unsubstituted or mono-substituted wherein the substitutents independently are selected from oxo and C 1-3 -alkyl; or

—CO—O—R OX2 ; wherein R OX2 represents

C 1-4 -alkyl;

2,2,2-trichloroethyl; or

tetrahydropyranyl;

R 2 represents C 1-4 -alkyl;

R 3 represents hydrogen; C 1-6 -alkyl; —CH 2 —C 3-6 -cycloalkyl; or C 2-4 -alkynyl;

R 4 represents a group —CO—NH—R 41 ; wherein R 41 represents

C 2-6 -alkyl, which is mono-substituted with C 1-4 -alkoxy, C 1-4 -fluoroalkoxy, or hydroxy;

C 1-3 -alkoxy-C 2-3 -alkylene-O—CH 2 —CH 2 —;

CH 2 —CH 2 —C 5-6 -heterocycloalkyl, wherein said C 5-6 -heterocycloalkyl contains one ring oxygen atom, wherein said C 5-6 -heterocyclyl is unsubstituted, mono- or di-substituted with C 1-4 -alkyl;

-L 1 -aryl; wherein L 1 represents —CH 2 —CH 2 —, —CH 2 —CH 2 —O—*, —CH 2 —CF 2 —*, —CH 2 -(cyclopropan-1,1-diyl)-*, —CH(CH 2 —OH)—CH 2 —*, or —CH 2 —CH(OH)—*; wherein asterisks indicate the bond with which L 1 is attached to the aryl; wherein aryl represents phenyl or naphthyl; wherein said aryl is unsubstituted, mono-, di- or tri-substituted, wherein the substituents are independently C 1-4 -alkyl, C 1-4 -alkoxy, C 1-3 -fluoroalkyl, C 1-3 -fluoroalkoxy, halogen, cyano, C 3-6 -cycloalkyl, C 3-6 -cycloalkyl-methyl, C 1-3 -alkoxy-C 1-3 -alkyl, hydroxy-C 1-3 -alkyl, C 2-3 -alkynyl, morpholin-4-yl, C 1-3 -alkyl-SO 2 —, 5- or 6-membered heteroaryl, or —NR N41 R N42 , wherein independently R N41 is hydrogen or C 1-4 -alkyl, and R N42 is hydrogen or C 1-4 -alkyl;

-L 2 -HET; wherein L 2 represents —CH 2 —CH 2 —, —CH 2 —CH 2 —O—*, —CH 2 —CF 2 —*, —CH 2 -(cyclopropan-1,1-diyl)-*, —CH(CH 2 —OH)—CH 2 —*, or —CH 2 —CH(OH)—*; wherein asterisks indicate the bond with which L 2 is attached to HET; wherein HET represents 5- to 10-membered heteroaryl, wherein said HET is independently unsubstituted, mono-, di- or tri-substituted, wherein the substituents are independently C 1-4 -alkyl; C 1-4 -alkoxy; C 1-3 -fluoroalkyl; C 1-3 -fluoroalkoxy; halogen; cyano; C 3-6 -cycloalkyl; C 3-6 -cycloalkyl-methyl; C 1-3 -alkoxy-C 1-3 -alkyl; hydroxy-C 1-3 -alkyl; C 2-3 -alkynyl; benzyl; or phenyl which is unsubstituted, mono- or di-substituted wherein the substituents independently are C 1-4 -alkyl, C 1-4 -alkoxy, or C 1-4 -fluoroalkoxy;

—CH 2 —CH 2 —HCy 1 , wherein HCy 1 represents a partially aromatic bicyclic ring system consisting of a phenyl ring which is fused to a 5- to 7-membered saturated heterocyclic ring containing one or two heteroatoms independently selected from oxygen and nitrogen, wherein, if present, said nitrogen when having a free valency is unsubstituted or mono-substituted with C 1-4 -alkyl; and wherein the phenyl ring of said partially aromatic bicyclic ring system is unsubstituted, mono-, di- or tri-substituted, wherein the substituents are independently C 1-4 -alkyl, C 1-4 -alkoxy, C 1-3 -fluoroalkyl, C 1-3 -fluoroalkoxy, halogen, or cyano;

—CH 2 —CH 2 —HCy 2 , wherein HCy 2 represents a partially aromatic bicyclic ring system consisting of a 5-membered heteroaryl which is fused to a 5- to 7-membered saturated carbocyclic ring; or

-L 3 -HCy 3 , wherein L 3 represents a direct bond, or —CH 2 —; wherein HCy 3 represents a partially aromatic bicyclic ring system consisting of a phenyl ring which is fused to a 5- to 7-membered saturated heterocyclic ring containing one oxygen atom; wherein L 3 is attached to said group HCy 3 at a carbon atom which is part of said 5- to 7-membered saturated heterocyclic ring; and wherein the phenyl ring of said partially aromatic bicyclic ring system is unsubstituted, or mono-substituted with C 1-4 -alkyl, C 1-4 -alkoxy, C 1-3 -fluoroalkyl, C 1-3 -fluoroalkoxy, halogen, or cyano;

Ar 1 represents

5- or 6-membered heteroarylene wherein said 5- or 6-membered heteroarylene is unsubstituted;

phenylene, or 5- or 6-membered heteroarylene; wherein said phenylene, or 5- or 6-membered heteroarylene independently is mono-, di- or tri-substituted, wherein the substituents are independently selected from C 1-4 -alkyl, C 1-4 -alkoxy, C 1-3 -fluoroalkyl, C 1-3 -fluoroalkoxy, cyano, and halogen;

phenylene wherein said phenylene is fused to a 5- or 6-membered saturated heterocyclic ring containing one or two oxygen atoms, wherein said 5- or 6-membered saturated heterocyclic ring independently is unsubstituted or di-substituted with fluoro; or

a bicyclic aromatic ring selected from naphthylene and 8- to 10-membered bicyclic heteroarylene; wherein said bicyclic aromatic ring independently is unsubstituted, mono-, or di-substituted, wherein the substituents are independently selected from C 1-4 -alkyl, C 1-3 -fluoroalkyl, C 1-4 -alkoxy, C 1-3 -fluoroalkoxy, cyano, and halogen; or

quinoline-diyl, wherein said quinoline-diyl is present in form of the respective N-oxide; wherein said quinoline-diyl N-oxide is unsubstituted, or said quinoline-diyl N-oxide is mono-substituted with methyl or fluoro;

and

Ar 2 represents

phenyl or naphthyl, wherein said phenyl or naphthyl independently is unsubstituted, mono- or di-substituted wherein the substituents are independently selected from C 1-4 -alkyl, C 1-3 -fluoroalkyl, halogen, cyano, C 1-6 -alkoxy, and C 1-3 -fluoroalkoxy;

5- or 6-membered heteroaryl, wherein said 5- or 6-membered heteroaryl independently is unsubstituted or mono-substituted wherein the substituents are independently selected from C 1-4 -alkyl, C 1-3 -fluoroalkyl, halogen, cyano, C 1-6 -alkoxy, and C 1-3 -fluoroalkoxy; or

9- or 10-membered heteroaryl;

or a pharmaceutically acceptable salt thereof.

2 . A compound of Formula (I) as defined for claim 1 , wherein the compounds are also compounds of Formula (I E ):

or a pharmaceutically acceptable salt thereof.

3 . A compound according to claim 1 ; wherein

X represents —CR X1 R X2 , wherein

R X1 and R X2 together with the carbon atom to which they are attached form a ring which is:

C 3-6 -cycloalkan-1,1-diyl-;

C 5-6 -cycloalkan-1,1-diyl- which is fused to a benzene ring; or

C 3-6 -cycloalkan-1,1-diyl-, wherein said C 3-6 -cycloalkan-1,1-diyl group is mono-substituted with C 1-3 -alkoxy, or di-substituted with fluoro;

R X1 and R X2 both independently represent C 1-4 -alkyl; or

R X1 represents hydrogen, and

R X2 represents

hydrogen;

C 1-6 -alkyl;

C 1-4 -fluoroalkyl;

C 3-6 -cycloalkyl;

C 1-3 -alkyl wherein said C 1-3 -alkyl is mono-substituted with

hydroxy;

C 1-4 -alkoxy;

-L X1 -C 3-6 cycloalkyl wherein said C 3-6 -cycloalkyl is unsubstituted or di-substituted with fluoro; and wherein L X1 independently represents a direct bond or oxygen;

C 4-6 -heterocycloalkyl wherein said C 4-6 -heterocycloalkyl contains one ring oxygen atom;

—NR N1 R N2 wherein R N1 and R N2 together with the nitrogen form a 4- to 6-membered carbocyclic ring comprising the nitrogen atom, wherein said ring is mono- or di-substituted with fluoro;

-L X2 -Ar X2 wherein—

C 1-4 -alkyl;

C 1-3 -alkoxy;

halogen;

cyano;

C 3-6 -cycloalkyl;

C 1-3 -fluoroalkyl; and

and

R 1 independently represents hydrogen or —C 1-3 -alkyl; or

X represents —CR X1 R X2 , wherein

R X1 represents hydrogen, and

R X2 represents hydrogen, or methyl; or

R X1 and R X2 together with the carbon atom to which they are attached form a ring which is C 3-5 -cycloalkan-1,1-diyl-;

and

R 1 independently represents

—C 4-6 -alkyl;

C 2-6 -alkyl, wherein said C 2-6 -alkyl is mono-substituted with C 1-4 -alkoxy;

C 3-6 -alkyl, wherein said C 3-6 -alkyl is mono-substituted with phenyl, or benzyloxy;

(CH 2 ) m —R 11 wherein m represents the integer 1 or 2; and R 11 independently represents

a saturated 5- or 6-membered heterocycloalkyl containing one or two ring oxygen atoms, wherein said 5- or 6-membered heterocycloalkyl is independently unsubstituted, mono- or di-substituted with C 1-4 -alkyl;

C 3-6 -cycloalkyl, wherein said C 3-6 -cycloalkyl is unsubstituted or mono-substituted with C 1-4 -alkoxy;

phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or 5- or 6-membered heteroaryl independently is unsubstituted, mono- or di-substituted wherein the substituents independently are selected from C 1-4 -alkyl, C 1-4 -alkoxy, C 1-3 -fluoroalkyl, C 1-3 -fluoroalkoxy, cyano or halogen;

a spirocyclic fragment, which is

a saturated bicyclic ring, which is

a partially aromatic bicyclic ring, which is

or the fragment

represents a heterocyclic ring which is

wherein R X represents

hydrogen;

C 1-4 -alkyl;

C 3-4 -cycloalkyl;

C 1-4 -alkyl, wherein said C 1-4 -alkyl is mono-substituted with C 3-4 -cycloalkyl;

C 2-4 -alkyl, wherein said C 2-4 -alkyl is mono-substituted with hydroxy, or C 1-3 -alkoxy;

wherein R SX1 represents hydrogen or —CO—O—C 1-4 -alkyl;

CO—R OX1 , or —SO 2 —R OX1 ; wherein R OX1 independently represents

C 1-4 -alkyl;

tetrahydropyranyl;

a group of the structure (R X-A ):

—CO—O—R OX2 ; wherein R OX2 represents

C 1-4 -alkyl;

2,2,2-trichloroethyl; or

tetrahydropyranyl;

or a pharmaceutically acceptable salt thereof.

4 . A compound according to claim 1 ; wherein the fragment

represents a group selected from:

wherein R X represents

C 1-4 -alkyl;

C 3-4 -cycloalkyl;

C 1-4 -alkyl, wherein said C 1-4 -alkyl is mono-substituted with C 3-4 -cycloalkyl;

C 1-4 -alkyl, wherein said C 1-4 -alkyl is mono-substituted with hydroxy, or C 1-3 -alkoxy;

phenyl;

6-membered heteroaryl, wherein said 6-membered heteroaryl is unsubstituted or mono-substituted with halogen;

wherein R SX1 represents —CO—O—C 1-4 -alkyl;

—CO—R OX1 , or —SO 2 —R OX1 ; wherein R OX1 independently represents

C 1-4 -alkyl;

tetrahydropyranyl;

phenyl which is unsubstituted, mono- or di-substituted wherein the substituents independently are C 1-3 -alkoxy, C 1-3 -fluoroalkoxy or halogen;

5- or 6-membered heteroaryl wherein said 5- or 6-membered heteroaryl is independently unsubstituted or mono-substituted with C 1-3 -alkoxy; or

a group of the structure (R X-A ):

—CO—O—R OX2 ; wherein R OX2 represents

C 1-4 -alkyl;

2,2,2-trichloroethyl; or

tetrahydropyranyl;

or H)

or a pharmaceutically acceptable salt thereof.

5 . A compound according to claim 1 ; wherein R 2 represents methyl;

or a pharmaceutically acceptable salt thereof.

6 . A compound according to claim 1 ; wherein R 3 represents isobutyl;

or a pharmaceutically acceptable salt thereof.

7 . A compound according to claim 1 ; wherein R 4 represents a group —CO—NH—R 41 ; wherein R 41 represents

C 2-6 -alkyl, which is mono-substituted with C 1-4 -alkoxy, or C 1-4 -fluoroalkoxy;

C 1-3 -alkoxy-C 2-3 -alkylene-O—CH 2 —CH 2 —;

—CH 2 —CH 2 —C 5-6 -heterocycloalkyl, wherein said C 5-6 -heterocycloalkyl contains one ring oxygen atom, wherein said C 5-6 -heterocyclyl is unsubstituted, mono- or di-substituted with C 1-4 -alkyl;

-L 1 -aryl; wherein L 1 represents —CH 2 —CH 2 —, —CH 2 —CH 2 —O—* or —CH 2 —CF 2 —*, —CH 2 -(cyclopropan-1,1-diyl)-*, —CH(CH 2 —OH)—CH 2 —*, or —CH 2 —CH(OH)—*; wherein asterisks indicate the bond with which L 1 is attached to the aryl; wherein aryl represents phenyl; wherein said aryl independently is unsubstituted, mono-, di- or tri-substituted, wherein the substituents are independently C 1-4 -alkyl, C 1-4 -alkoxy, C 1-3 -fluoroalkyl, C 1-3 -fluoroalkoxy, halogen, cyano, hydroxy-C 1-3 -alkyl, C 2-3 -alkynyl, morpholin-4-yl, C 1-3 -alkyl-SO 2 —, 5- or 6-membered heteroaryl, or —NR N41 R N42 , wherein independently R N4 1 is hydrogen or C 1-4 -alkyl, and R N42 is hydrogen or C 1-4 -alkyl;

-L 2 -HET 1 ; wherein L 2 represents —CH 2 —CH 2 —, —CH 2 —CF 2 —*, —CH 2 -(cyclopropan-1,1-diyl)-*, or —CH 2 —CH(OH)—*; wherein asterisks indicate the bond with which L 2 is attached to HET 1 ; wherein HET 1 represents 5- or 6-membered heteroaryl, wherein said 5- or 6-membered heteroaryl is independently unsubstituted, mono-, or di-substituted, wherein the substituents are independently C 1-4 -alkyl; C 1-4 -alkoxy; C 1-3 -fluoroalkyl; halogen; C 3-6 -cycloalkyl; C 3-6 -cycloalkyl-methyl; C 1-3 -alkoxy-C 1-3 -alkyl; C 2-3 -alkynyl, benzyl; or phenyl which is unsubstituted, mono- or di-substituted wherein the substituents independently are C 1-4 -alkyl, C 1-4 -alkoxy, or C 1-4 -fluoroalkoxy;

—CH 2 —CH 2 —HET 2 , wherein HET 2 represents 9- or 10-membered bicyclic heteroaryl, wherein said HET 2 is unsubstituted;

—CH 2 —CH 2 —HCy 1 , wherein HCy 1 represents a partially aromatic bicyclic ring system consisting of a phenyl ring which is fused to a 5- to 7-membered saturated heterocyclic ring containing one or two heteroatoms independently selected from oxygen and nitrogen, wherein, if present, said nitrogen when having a free valency is unsubstituted or mono-substituted with C 1-4 -alkyl; and wherein the phenyl ring of said partially aromatic bicyclic ring system is unsubstituted, mono-, or di-substituted, wherein the substituents are independently C 1-4 -alkyl, C 1-4 -alkoxy, or halogen; or

—CH 2 —CH 2 —HCy 2 , wherein HCy 2 represents a partially aromatic bicyclic ring system consisting of a 5-membered heteroaryl which is fused to a 5- to 7-membered saturated carbocyclic ring;

or a pharmaceutically acceptable salt thereof.

8 . A compound according to claim 1 ; wherein Ar 2 represents phenyl;

or a pharmaceutically acceptable salt thereof.

9 . A compound according to claim 1 , wherein Ar 1 represents

phenylene, or 5- or 6-membered heteroarylene; wherein said phenylene, or 5- or 6-membered heteroarylene independently is mono-, or di-substituted, wherein the substituents are independently selected from C 1-4 -alkyl, C 1-4 -alkoxy, and halogen;

a bicyclic aromatic ring selected from naphthylene and 8- to 10-membered bicyclic heteroarylene; wherein said bicyclic aromatic ring independently is unsubstituted, or mono-substituted, wherein the substituents are independently selected from C 1-4 -alkyl, and halogen;

or a pharmaceutically acceptable salt thereof.

10 . A compound according to claim 1 wherein said compound is the compound of example 1; 2; 3; 4; 5; 6; 7; 8; 9; 10; 11; 12; 13; 14; 15; 16; 17; 18; 19; 20; 21; 22; 23; 24; 25; 26; 27; 28; 29; 30; 31; 32; 33; 34; 35; 36; 37; 38; 39; 40; 41; 42; 43; 44; 45; 46; 47; 48; 49; 50; 51; 52; 53; 54; 55; 56; 57; 58; 59; 60; 61; 62; 63; 64; 65; 66; 67; 68; 69; 70; 71; 72; 73; 74; 75; 76; 77; 78; 79; 80; 81; 82; 83; 84; 85; 86; 87; 88; 89; 90; 91; 92; 93; 94; 95; 96; 97; 98; 99; 100; 101; 102; 103; 104; 105; 106; 107; 108; 109; 110; 111; 112; 113; 114; 115; 116; 117; 118; 119; 120; 121; 122; 123; 124; 125; 126; 127; 128; 129; 130; 131; 132; 133; 134; 135; 136; 137; 138; 139; 140; 141; 142; 143; 144; 145; 146; 147; 148; 149; 150; 151; 152; 153; 154; 155; 156; 157; 158; 159; 160; 161; 162; 163; 164; 165; 166; 167; 168; 169; 170; 171; 172; 173; 174; 175; 176; 177; 178; 179; 180; 181; 182; 183; 184; 185; 186; 187; 188; 189; 190; 191; 192; 193; 194; 195; 196; 197; 198; 199; 200; 201; 202; 203; 204; 205; 206; 207; 208; 209; 210; 211; 212; 213; 214; 215; 216; 217; 218; 219; 220; 221; 222; 223; 224; 225; 226; 227; 228; 229; 230; 231; 232; 233; 234; 235; 236; 237; 238; 239; 240; 241; 242; 243; 244; 245; 246; 247; 248; 249; 250; 251; 252; 253; 254; 255; 256; 257; 258; 259; 260; 261; 262; 263; 264; 265; 266; 267; 268; 269; 270; 271; 272; 273; 274; 275; 276; 277; 278; 279; 280; 281; 282; 283; 284; 285; 286; 287; 288; 289; 290; 291; 292; 293; 294; 295; 296; 297; 298; 299; 300; 301; 302; 303; 304; 305; 306; 307; 308; 309; 310; 311; 312; 313; 314; 315; 316; 317; 318; 319; 320; 321; 322; 323; 324; 325; 326; 327; 328; 329; 330; 331; 332; 333; 334; 335; 336; 337; 338; 339; 340; 341; 342; 343; 344; 345; 346; 347; 348; 349; 350; 351; 352; 353; 354; 355; 356; 357; 358; 359; 360; 361; 362; 363; 364; 365; 366; 367; 368; 369; 370; 371; 372; 373; 374; 375; 376; 377; 378; 379; 380; 381; 382; 383; 384; 385; 386; 387; 388; 389; 390; 391; 392; 393; 394; 395; 396; 397; 398; 399; 400; 401; 402; 403; 404; 405; 406; 407; 408; 409; 410; 411; 412; 413; 414; 415; 416; 417; 418; 419; 420; 421; 422; 423; 424; 425; 426; 427; 428; 429; 430; 431; 432; 433; 434; 435; 436; 437; 438; 439; 440; 441; 442; 443; 444; 445; 446; 447; 448; 449; 450; 451; 452; 453; 454; 455; 456; 457; 458; 459; 460; 461; 462; 463; 464; 465; 466; 467; 468; 469; 470; 471; 472; 473; 474; 475; 476; 477; 478; 479; 480; 481; 482; 483; 484; 485; 486; 487; 488; 489; 490; 491; 492; 493; 494; 495; 496; 497; 498; 499; 500; 501; 502; 503; 504; 505; 506; 507; 508; 509; 510; 511; 512; 513; 514; 515; 516; 517; 518; 519; 520; 521; 522; 523; 524; 525; 526; 527; 528; 529; 530; 531; 532; 533; 534; 535; 536; 537; 538; 539; 540; 541; 542; 543; 544; 545; 546; 547; 548; 549; 550; 551; 552; 553; 554; 555; 556; 557; 558; 559; 560; 561; 562; 563; 564; 565; 566; 567; 568; 569; 570; 571; 572; 573; 574; 575; 576; 577; 578; 579; 580; 581; 582; 583; 584; 585; 586; 587; 588; 589; 590; 591; 592; 593; 594; 595; 596; 597; 598; 599; 600; 601; 602; 603; 604; 605; 606; 607; 608; 609; 610; 611; 612; 613; 614; 615; 616; 617; 618; 619; 620; 621; 622; 623; 624; 625; 626; 627; 628; 629; 630; 631; 632; 633; 634; 635; 636; 637; 638; 639; 640; 641; 642; 643; 644; 645; 646; 647; 648; 649; 650; 651; 652; 653; 654; 655; 656; 657; 658; 659; 660; 661; 662; 663; 664; 665; 666; 667; 668; 669; 670; 671; 672; 673; 674; 675; 676; 677; 678; 679; 680; 681; 682; 683; 684; 685; 686; 689; 690; 691; 692; 693; 694; 695; 696; 697; 698; 699; 700; 701; 702; 703; 704; 705; 706; 707; 708; 709; 710; 711; 712; 713; 714; 715; 716; 717; 718; 719; 720; 721; 722; 723; 724; 725; 726; 727; 728; 729; 730; 731; 732; 733; 734; 735; 736; 737; 738; 739; 740; 741; 742; 743; 744; 745; 746; 747; 748; 749; 750; 751; 752; 753; 754; 755; 756; 757; 758; 759; 760; 761; 762; 763; 764; 765; 766; 767; 768; 769; 770; 771; 772; 773; 774; 775; 776; 777; 778; 779; 780; 781; 782; 783; 784; 785; 786; 787; 788; 789; 790; 791; 792; 793; 794; 795; 796; 797; 798; 799; 800; 801; 802; 803; 804; 805; 806; 807; 808; 809; 810; 811; 812; 813; 814; 815; 816; 817; 818; 819; 820; 821; 822; 823; 824; 825; 826; 827; 828; 829; 830; 831; 832; 833; 834; 835; 836; 837; 838; 839; 840; 841; 842; 843; 844; 845; 846; 847; 848; 849; 850; 851; 852; 853; 854; 855; 856; 857; 858; 859; 860; 861; 862; 863; 864; 865; 866; 867; 868; 869; 870; 871; 872; 873; 874; 875; 876; 877; 878; 879; 880; 881; 882; 883; 884; 885; 886; 887; 888; 889; 890; 891; 892; 893; 894; 895; 896; 897; 898; 899; 900; 901; 902; 903; 904; 905; 906; 907; 908; 909; 910; 911; 912; 913; 914; 915; 916; 917; 918; 919; 920; 921; 922; 923; 924; 925; 926; 927; 928; 929; 930; 931; 932; 933; 934; 935; 936; 937; 938; 939; 940; 941; 942; 943; 944; 945; 946; 947; 948; 949; 950; 951; 952; 953; 954; 955; 956; 957; 958; 959; 960; 961; 962; 963; 964; 965; 966; 967; 968; 969; 970; 971; 972; 973; 974; 975; 976; 977; 978; 979; 980; 981; 982; or 983;

or a pharmaceutically acceptable salt thereof.

11 . A method for treatment of cystic fibrosis, said method comprising administering to a subject in need thereof an effective amount of a compound of Formula (II)

wherein X, R 1 , R 2 , R 3 , R 4 , Ar 2 are as defined for the compounds of Formula (I) according to claim 1 ; and

Ar 1 represents

phenylene wherein said phenylene is unsubstituted;

5- or 6-membered heteroarylene wherein said 5- or 6-membered heteroarylene is unsubstituted;

a bicyclic ring selected from naphthylene and 8- to 10-membered bicyclic heteroarylene; wherein said bicyclic ring independently is unsubstituted, mono-, or di-substituted, wherein the substituents are independently selected from C 1-4 -alkyl, C 1-3 -fluoroalkyl, C 1-4 -alkoxy, C 1-3 -fluoroalkoxy, cyano, and halogen; or

or a pharmaceutically acceptable salt thereof.

12 . A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

13 - 14 . (canceled)

15 . A method of treatment of CFTR-related diseases and disorders, said method comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 , or of a pharmaceutically acceptable salt thereof.

16 . A method according to claim 15 , wherein said method is for treatment of cystic fibrosis.

17 . A compound according to claim 1 , wherein said compound is (3S,7S,10R,13R)-13-benzyl-20-fluoro-7-isobutyl-N-(2-(3-methoxy-1,2,4-oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-[1]oxa[4,7,10,14]tetraazacycloheptadecino[16,17-f]quinoline-3-carboxamide:

or a pharmaceutically acceptable salt thereof.

18 . A pharmaceutical composition comprising a compound according to claim 10 , or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

19 . A pharmaceutical composition comprising the compound according to claim 17 , or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

20 . A method of treatment of CFTR-related diseases and disorders, said method comprising administering to a subject in need thereof an effective amount of a compound according to claim 10 , or of a pharmaceutically acceptable salt thereof.

21 . A method according to claim 20 , wherein said method is for treatment of cystic fibrosis.

22 . A method of treatment of CFTR-related diseases and disorders, said method comprising administering to a subject in need thereof an effective amount of the compound according to claim 17 , or of a pharmaceutically acceptable salt thereof.

23 . A method according to claim 22 , wherein said method is for treatment of cystic fibrosis.

Assignments (2)

PATENT SECURITY AGREEMENT Recorded Jun 25, 2026

From: IDORSIA PHARMACEUTICALS LTD

To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT

Reel/Frame 076038/0461 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2023

From: BOLLI, MARTIN; BROTSCHI, CHRISTINE; COMMANDEUR, MALGORZATA; GATFIELD, JOHN; KIMMERLIN, THIERRY; SIENDT, HERVÉ; SPRINGER, JASPER; WAGNER, CLEMENS; WEGERT, ANITA; WILLIAMS, JODI T.

To: IDORSIA PHARMACEUTICALS LTD

Reel/Frame 065776/0682 →